# Nimotuzumab Plus Nab-paclitaxel and Cisplatin in Treating Patients With Advanced Esophageal Carcinoma

> **NCT02034968** · PHASE2 · WITHDRAWN · sponsor: **Zhejiang University**

## Conditions studied

- Stage IV Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** Nimotuzumab

## Key facts

- **NCT ID:** NCT02034968
- **Lead sponsor:** Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-02
- **Primary completion:** 2016-01
- **Final completion:** 2017-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No recruitment
- **Last updated:** 2015-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02034968

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02034968, "Nimotuzumab Plus Nab-paclitaxel and Cisplatin in Treating Patients With Advanced Esophageal Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02034968. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*